Interpretation of the Newly Released European Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries：Improving the Ability of Hierarchical Diagnosis and Treatment，and Strengthening the Joint Management of General Practitioners and Specialist Physicians

doi:10.12114/j.issn.1007-9572.2020.00.632

Abstract

Abstract: Ischaemia with non-obstructive coronary arteries（INOCA）refers to a disease with suspected ischemic symptoms，while no obstructive coronary artery stenosis（stenosis degree ≥50%）is found by coronary angiography.The disease is prevalent but individuals with INOCA are significantly undertreated.Recently，an EAPCI expert consensus document was released on ischaemia with non-obstructive coronary arteries in collaboration with European society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group.We interpreted the consensus document from the aspects of INOCA endotypes，epidemiology，risk factors，pathophysiology mechanism，clinical features，prognostic significance，noninvasive and invasive diagnostic methods，and patient management and medication，in order to raise awareness of clinicians for INOCA，prompt them to put a high value on INOCA endotypes and take tailored treatment，with the ultimate goals of improving angina symptoms and prognosis of patients with INOCA，and reducing medical cost.

Key words: Coronary artery disease, Microvascular angina, Coronary vasospasm, Myocardial ischemia, Angina pectoris, Expert consensus, Unscramble

摘要：

非阻塞性冠状动脉缺血疾病（INOCA）是指具有可疑缺血相关症状，但经冠状动脉造影检查没有发现阻塞性冠状动脉狭窄（狭窄程度≥50%）的疾病。该疾病患者人群广泛而治疗不足。近日，欧洲经皮心血管介入学会（EAPCI）与欧洲心脏病学会（ESC）冠状动脉病理生理学和微循环工作组联合发布了《欧洲非阻塞性冠状动脉缺血疾病专家共识》。本文结合欧洲专家共识对INOCA的亚型、患病率、危险因素、病理生理学机制、临床特征、预后意义、无创及侵入性诊断方法、患者管理和药物治疗等内容进行解读，以期提高临床医生对这类患者的认识，使其重视对疾病亚型的分类，采取个体化的治疗策略，改善患者症状及预后，降低医疗消耗。

关键词: 冠状动脉疾病, 微血管性心绞痛, 冠状血管痉挛, 心肌缺血, 心绞痛, 专家共识, 解读

HUANG Baotao,CHEN Mao. Interpretation of the Newly Released European Expert Consensus Document on Ischaemia with Non-Obstructive Coronary Arteries：Improving the Ability of Hierarchical Diagnosis and Treatment，and Strengthening the Joint Management of General Practitioners and Specialist Physicians　[J]. Chinese General Practice, 2021, 24(2): 125-131. DOI: 10.12114/j.issn.1007-9572.2020.00.632.
黄宝涛,陈茂. 《2020年欧洲非阻塞性冠状动脉缺血疾病专家共识》解读——提高分级诊疗能力，加强全-专联合管理[J]. 中国全科医学, 2021, 24(2): 125-131. DOI: 10.12114/j.issn.1007-9572.2020.00.632.

References

［1］GBD MORTALITY AND CAUSES OF DEATH COLLABORATORS.Global，regional，and national life expectancy，all-cause mortality，and cause-specific mortality for 249 causes of death，1980-2015：a systematic analysis for the Global Burden of Disease Study 2015［J］．Lancet（London，England），2016，388（10053）：1459-1544．DOI：10.1016/S0140-6736（16）31012-1.
［2］REEH J，THERMING C B，HEITMANN M，et al．Prediction of obstructive coronary artery disease and prognosis in patients with suspected stable angina［J］．Eur Heart J，2019，40（18）：1426-1435．DOI：10.1093/eurheartj/ehy806.
［3］KUNADIAN V，CHIEFFO A，CAMICI P G，et al．An EAPCI expert consensus document on ischaemia with non-obstructive coronary arteries in collaboration with European society of cardiology working group on coronary pathophysiology & microcirculation endorsed by coronary vasomotor disorders international study group［J］．Eur Heart J，2020：ehaa503．DOI：10.1093/eurheartj/ehaa503.
［4］FORD T J，YII E，SIDIK N，et al．Ischemia and No obstructive coronary artery disease：prevalence and correlates of coronary vasomotion disorders［J］．Circ Cardiovasc Interv，2019，12（12）：e008126．DOI：10.1161/CIRCINTERVENTIONS.119.008126.
［5］PATEL M R，PETERSON E D，DAI D，et al．Low diagnostic yield of elective coronary angiography［J］．N Engl J Med，2010，362（10）：886-895．DOI：10.1056/NEJMoa0907272.
［6］JESPERSEN L，HVELPLUND A，ABILDSTRØM S Z，et al．Stable angina pectoris with no obstructive coronary artery disease is associated with increased risks of major adverse cardiovascular events［J］．Eur Heart J，2012，33（6）：734-744．DOI：10.1093/eurheartj/ehr331.
［7］WESSEL T R，ARANT C B，MCGORRAY S P，et al．Coronary microvascular reactivity is only partially predicted by atherosclerosis risk factors or coronary artery disease in women evaluated for suspected ischemia：results from the NHLBI Women's Ischemia Syndrome Evaluation（WISE）［J］．Clin Cardiol，2007，30（2）：69-74．DOI：10.1002/clc.19.
［8］BELTRAME J F，SASAYAMA S，MASERI A.Racial heterogeneity in coronary artery vasomotor reactivity：differences between Japanese and Caucasian patients［J］．J Am Coll Cardiol，1999，33（6）：1442-1452．DOI：10.1016/s0735-1097（99）00073-x.
［9］SUEDA S，KOHNO H，FUKUDA H，et al．Frequency of provoked coronary spasms in patients undergoing coronary arteriography using a spasm provocation test via intracoronary administration of ergonovine［J］．Angiology，2004，55（4）：403-411．DOI：10.1177/000331970405500407.
［10］HUNG M Y，HSU K H，HUNG M J，et al．Interactions among gender，age，hypertension and C-reactive protein in coronary vasospasm［J］．Eur J Clin Invest，2010，40（12）：1094-1103．DOI：10.1111/j.1365-2362.2010.02360.x.
［11］BERTRAND M E，LABLANCHE J M，TILMANT P Y，et al．Frequency of provoked coronary arterial spasm in 1089 consecutive patients undergoing coronary arteriography［J］．Circulation，1982，65（7）：1299-1306．DOI：10.1161/01.cir.65.7.1299.
［12］HUNG M J，CHERNG W J，CHENG C W，et al．Comparison of serum levels of inflammatory markers in patients with coronary vasospasm without significant fixed coronary artery disease versus patients with stable angina pectoris and acute coronary syndromes with significant fixed coronary artery disease［J］．Am J Cardiol，2006，97（10）：1429-1434．DOI：10.1016/j.amjcard.2005.12.035.
［13］MEJÍA-RENTERÍA H，VAN DER HOEVEN N，VAN DE HOEF T P，et al．Targeting the dominant mechanism of coronary microvascular dysfunction with intracoronary physiology tests［J］．Int J Cardiovasc Imaging，2017，33（7）：1041-1059．DOI：10.1007/s10554-017-1136-9.
［14］BAIREY MERZ C N，PEPINE C J，WALSH M N，et al．Ischemia and no obstructive coronary artery disease（INOCA）：Developing evidence-based therapies and research agenda for the next decade［J］．Circulation，2017，135（11）：1075-1092．DOI：10.1161/CIRCULATIONAHA.116.024534.
［15］BRAININ P，FRESTAD D，PRESCOTT E.The prognostic value of coronary endothelial and microvascular dysfunction in subjects with normal or non-obstructive coronary artery disease：A systematic review and meta-analysis［J］．Int J Cardiol，2018，254：1-9．DOI：10.1016/j.ijcard.2017.10.052.
［16］KNUUTI J，WIJNS W，SARASTE A，et al．2019 ESC Guidelines for the diagnosis and management of chronic coronary syndromes［J］．Eur Heart J，2020，41（3）：407-477．DOI：10.1093/eurheartj/ehz425.
［17］SHEIKH A R，ZEITZ C J，RAJENDRAN S，et al．Clinical and coronary haemodynamic determinants of recurrent chest pain in patients without obstructive coronary artery disease-A pilot study［J］．Int J Cardiol，2018，267：16-21．DOI：10.1016/j.ijcard.2018.04.077.
［18］WILLIAMS R P，DE WAARD G A，DE SILVA K，et al．Doppler versus thermodilution-derived coronary microvascular resistance to predict coronary microvascular dysfunction in patients with acute myocardial infarction or stable angina pectoris［J］．Am J Cardiol，2018，121（1）：1-8．DOI：10.1016/j.amjcard.2017.09.012.
［19］NEUMANN F J，SOUSA-UVA M，AHLSSON A，et al．2018 ESC/EACTS Guidelines on myocardial revascularization［J］．Eur Heart J，2019，40（2）：87-165．DOI：10.1093/eurheartj/ehy394.
［20］中华医学会心血管病学分会基础研究学组，中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会女性心脏健康学组，等．冠状动脉微血管疾病诊断和治疗的中国专家共识［J］．中国循环杂志，2017，32（5）：421-430．DOI：10.3969/j.issn.1000-3614.2017.05.003.
［21］中华医学会心血管病学分会介入心脏病学组，中华医学会心血管病学分会动脉粥样硬化与冠心病学组，中国医师协会心血管内科医师分会血栓防治专业委员会，等．稳定性冠心病诊断与治疗指南［J］ .中华心血管病杂志，2018，46（9）：680-694．DOI：10.3760/cma.j.issn.0253-3758.2018.09.004.
［22］FORD T J，STANLEY B，GOOD R，et al．Stratified medical therapy using invasive coronary function testing in angina：The CorMicA Trial［J］．J Am Coll Cardiol，2018，72（23 Pt A）：2841-2855．DOI：10.1016/j.jacc.2018.09.006.
［23］MEHTA P K，SHARMA S，MINISSIAN M，et al．Ranolazine reduces angina in women with ischemic heart disease：Results of an open-label，multicenter trial［J］．J Womens Health（Larchmt），2019，28（5）：573-582．DOI：10.1089/jwh.2018.7019.
［24］KRONHAUS K D，LAWSON W E.71 enhanced external counterpulsation improves microvascular angina in coronary artery disease patients［J］．J Invest Med，2005，53（2）：S399．DOI：10.2310/6650.2005.00205.70.

[1]	WANG Qiushi, LI Hongwei. The Predictive Value of CHA₂DS₂-VASc Score on Major Adverse Cardiovascular Events in Patients with Three Vessels or Left Main Diseases of Coronary Heart Disease [J]. Chinese General Practice, 2023, 26(33): 4130-4136.
[2]	CHEN Jing, ZOU Tao, ZHAO Danqing, XIAO Ziwen, WU Xianqing, Chinese Medical Association Psychosomatic Medicine Branch Perinatal Mental Disorders Collaborative Group. Expert Consensus on Screening, Diagnosis and Treatment of Perinatal Mental Disorders [J]. Chinese General Practice, 2023, 26(28): 3463-3470.
[3]	GAO Yang, WANG Yunxia, ZHANG You, GAO Chuanyu. Lipid Goal Attainment Rate and Influencing Factors in 45-year-old or Younger Acute Coronary Syndrome Patients with an Ultra-high Risk of Atherosclerotic Cardiovascular Disease after Lipid-lowering Treatment [J]. Chinese General Practice, 2023, 26(27): 3383-3387.
[4]	YUAN Mingpei, LIN Yaowang, BEI Weijie, LIU Huadong, DONG Shaohong, SUN Xin. Feasibility of Retrograde Recanalization of Occluded Radial Artery via Distal Transradial Artery Approach: a Single-center Prospective Study [J]. Chinese General Practice, 2023, 26(27): 3373-3377.
[5]	CAI Gaojun, SHI Ganwei, LI Feng, LI Wenhua, YAN Yongmin, XUE Sheliang, XIAO Jianqiang, GU Jun, SONG Yanbin, ZHANG Liuyan, LU Wei, GONG Chun. How to Improve the Success Puncture Rate of Distal Transradial Artery Approach, "Winding Path to the Secluded": Summary of the Experience of More than 2 000 Cases [J]. Chinese General Practice, 2023, 26(27): 3361-3365.
[6]	LIU Minghao, WANG Pan, GAO Lijian, XU Shuqing, WANG Huanhuan, ZHAO Guangxian, CHEN Jue, QIAO Shubin, XU Bo, YUAN Jinqing. Feasibility, Safety and Timing of Secondary Percutaneous Coronary Intervention via Distal Transradial Artery Approach [J]. Chinese General Practice, 2023, 26(27): 3366-3372.
[7]	LAN Yonghao, KE Erqin, HAN Rui, MEI Yingchen, LIU Wei. Percutaneous Coronary Intervention via Distal Transradial Approach: Strengths, Weaknesses, Opportunities and Challenges [J]. Chinese General Practice, 2023, 26(27): 3355-3360.
[8]	Expert group of expert consensus on the application of ulinastatin in common clinical critical illness. Expert Consensus on the Application of Ulinastatin in Common Clinical Critical Illness [J]. Chinese General Practice, 2023, 26(26): 3207-3219.
[9]	Chinese Medical Association Clinical Pharmacy Branch, Shanghai Medical Association Clinical Pharmacy Branch, Shanghai Pharmacy Association Hospital Pharmacy Professional Committee. Expert Consensus on Construction and Application of the Internet Medical Intelligent Auxiliary Prescription Review System [J]. Chinese General Practice, 2023, 26(25): 3079-3090.
[10]	CHEN Yan, LYU Zhibo, ZHAO Xin. Correlation of Discordance between Remnant Lipoprotein Cholesterol and Non-high-density Lipoprotein Cholesterol and Severity of Coronary Stenosis [J]. Chinese General Practice, 2023, 26(24): 3010-3015.
[11]	ZHANG Yunxu, WANG Tingting, WEI Junling, XING Yanyun, SU Li. A Newly Discovered Disease Affecting Women's Physical and Mental Health: Research Status and Expert Consensus Interpretation of Persistent Genital Arousal Disorder [J]. Chinese General Practice, 2023, 26(23): 2830-2835.
[12]	National Center of Gerontology, Electrocardiology and Cardiac Function Branch of Chinese Geriatric Society, Imaging Group of Cardiovascular Department, Beijing Medical Association, Chinese Medical and Health Culture Association Cardiovascular Health and Science Sports Branch of China Health Culture Association. Expert Consensus for Management of Myocardial Injury, Myocarditis, and Post-infection Condition with Coronavirus Disease 2019 (Second Edition) [J]. Chinese General Practice, 2023, 26(14): 1692-1702.
[13]	CHAI Yan, ZHAO Yuqing, GUO Xunan, WANG Dongying, BIAN Yunfei. Bioinformatics Analysis of the Role of Epicardial Adipose Tissue in Coronary Artery Disease [J]. Chinese General Practice, 2023, 26(08): 939-950.
[14]	TIAN Xintong, MA Teng, SUN Xuan, YANG Ji, ZHAO Yingqiang. Clinical Guidelines Analysis and Quality Assessment of Guidelines for Hypertension in the Elderly [J]. Chinese General Practice, 2022, 25(34): 4259-4266,4285.
[15]	Writing Group for the Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease. Expert Consensus on Immunomodulatory Therapies for Chronic Obstructive Pulmonary Disease [J]. Chinese General Practice, 2022, 25(24): 2947-2959.